Hosted on MSN1mon
Sonnet BioTherapeutics to expand trial of SON-1010 with trabectedin for solid tumoursUS-based biotechnology company Sonnet BioTherapeutics has expanded its Phase I SB101 study of SON-1010 for advanced solid tumours. The company is adding a cohort to assess the efficacy of SON-1010 ...
Completion of SON-1010 (IL12-FHAB) monotherapy dose escalation in Phase 1 SB101 trial; Stable disease (SD) at four months post-initiation of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback